Bibliography
- Rohrmann K, Staehler M, Haseke N, et al. Immunotherapy in metastatic renal cell carcinoma. World J Urol 2005;23:196-201
- Parmar S, Rademaker AW, Fung BB, Kuzel T. High dose IL-2 is associated with durable disease free survival and clinically important improvement in overall survival in metastatic renal cell cancer. Proc Am Soc Clin Oncol 2003;22:(abstr 1630)
- Motzer RJ, Mazumdar M, Bacik J, et al. Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J Clin Oncol 2000;18:1928-35
- Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus Interferon alpha in metastatic renal cell carcinoma. N Engl J Med 2007;356(2):115-24
- Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alpha in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:3584-90
- Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell-renal-cell carcinoma. N Engl J Med 2007;356(2):125-34
- Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the Phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009;27(20):3312-18
- Bailey K. Generalizing the results of randomized clinical trials. Control Clin Trials 1994;15:15-23
- Choueiri TK, Duh MS, Clement J, et al. Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review. BJU Int 2010;105(9):1247-54
- Feinberg BA, Jolly P, Wang S, et al. Safety and treatment patterns of angiogenesis inhibitors in patients with metastastic renal cell carcinoma: evidence from US community oncology clinics. Med Oncol 2012;29(2):786-94
- Porta C, Paglino C, Imarisio I, et al. Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy. BMC Cancer 2011;11:105
- Hong MH, Kim HS, Kim C, et al. Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea. Cancer Res Treat 2009;41(2):67-72
- Hwang E, Lee HJ, Sul CK, Lim JS. Efficacy and safety of sunitinib on metastatic renal cell carcinoma: a single institution experience. Korean J Urol 2010;51(7):450-5
- Ansari J, Fatima A, Fernando K, et al. Sunitinib in patients with metastatic renal cell carcinoma: Birmingham experience. Oncol Rep 2010;24(2):507-10
- Ueda T, Imamura Y, Komaru A, et al. Treatment outcomes of sorafenib for first line or cytokine refractory advanced renal cell carcinoma in Japanese patients. Int J Urol 2010;17:811-16
- Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. Available from: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf [Last accessed June 2012]
- Highlights of Prescribing Information for Sunitinib. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021938s13s17s18lbl.pdf [Last accessed 14 February 2013]
- Highlights of Prescribing Information for Sorafenib. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021923s004s005s006s007lbl.pdf [Last accessed 14 February 2013]
- Gore ME, Szczylik C, Porta C, et al. Safety and efficacy of sunitinib for metastatic renal cell carcinoma: an expanded access trial. Lancet Oncol 2009;10(8):757-63
- Stadler AM, Figlin RA, McDermott DF, et al. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer 2010;116:1272-80
- Oudard S, Porta C, Castellano D, et al. The association between treatment modifications due to adverse events and overall survival in patients with advanced renal cell carcinoma (RCC) treated with sunitinib and sorafenib: results from a multi-country study in Europe. European Multidisciplinary Cancer Congress; 2011
- Kim HS, Hong MH, Kim K, et al. Sunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles. Oncology 2011;80(5-6):395-405
- Kawashima A, Tsujimura A, Takayama H, et al. Importance of continuing therapy and maintaining one-month relative dose intensity in sunitinib therapy for metastatic renal cell carcinoma. Med Oncol 2012;29(5):3298-305
- Tanigawa G, Kawashima A, Yamaguchi S, et al. Clinical outcome and prognostic factors of sorafenib in Japanese patients with advanced renal cell carcinoma in general clinical practice. Jpn J Clin Oncol 2011;41(11):1265-70
- Kawashima A, Takayama H, Arai Y, et al. One-month relative dose intensity of not less than 50% predicts favourable progression-free survival in sorafenib therapy for advanced renal cell carcinoma in Japanese patients. Eur J Cancer 2011;47(10):1521-6